Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Surgery
Volume 2015 (2015), Article ID 321682, 5 pages
http://dx.doi.org/10.1155/2015/321682
Case Report

Application of Intrawound Vancomycin Powder during Spine Surgery in a Patient with Dialysis-Dependent Renal Failure

1Department of Neurosurgery, Tufts Medical Center, Boston, MA 02111, USA
2Department of Neurosurgery, Tufts University School of Medicine, Boston, MA 02111, USA
3Boston University, Boston, MA 02215, USA

Received 27 February 2015; Accepted 15 June 2015

Academic Editor: Giovanni Mariscalco

Copyright © 2015 Jackson Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Bible, D. Biswas, and C. J. Devin, “Postoperative infections of the spine,” The American Journal of Orthopedics, vol. 40, no. 12, pp. E264–E271, 2011. View at Google Scholar · View at Scopus
  2. A. Gerometta, J. C. R. Olaverri, and F. Bitan, “Infections in spinal instrumentation,” International Orthopaedics, vol. 36, no. 2, pp. 457–464, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. D. S. Meredith, C. K. Kepler, R. C. Huang, B. D. Brause, and O. Boachie-Adjei, “Postoperative infections of the lumbar spine: presentation and management,” International Orthopaedics, vol. 36, no. 2, pp. 439–444, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. R. W. Molinari, O. A. Khera, and W. J. Molinari III, “Prophylactic intraoperative powdered vancomycin and postoperative deep spinal wound infection: 1,512 consecutive surgical cases over a 6-year period,” European Spine Journal, vol. 21, supplement 4, pp. S476–S482, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. K. R. O'Neill, J. G. Smith, A. M. Abtahi et al., “Reduced surgical site infections in patients undergoing posterior spinal stabilization of traumatic injuries using vancomycin powder,” The Spine Journal, vol. 11, no. 7, pp. 641–646, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. F. A. Sweet, M. Roh, and C. Sliva, “Intrawound application of vancomycin for prophylaxis in instrumented thoracolumbar fusions: efficacy, drug levels, and patient outcomes,” Spine, vol. 36, no. 24, pp. 2084–2088, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Pahys, J. R. Pahys, S. K. Cho et al., “Methods to decrease postoperative infections following posterior cervical spine surgery,” The Journal of Bone & Joint Surgery—American Volume, vol. 95, no. 6, pp. 549–554, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Beiner, J. Grauer, B. K. Kwon, and A. R. Vaccaro, “Postoperative wound infections of the spine,” Neurosurgical Focus, vol. 15, no. 3, article E14, 2003. View at Google Scholar · View at Scopus
  9. C. Caroom, J. M. Tullar, E. G. Benton Jr., J. R. Jones, and C. D. Chaput, “Intrawound vancomycin powder reduces surgical site infections in posterior cervical fusion,” Spine, vol. 38, no. 14, pp. 1183–1187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. M. Cizik, M. J. Lee, B. I. Martin et al., “Using the spine surgical invasiveness index to identify risk of surgical site infection: a multivariate analysis,” The Journal of Bone & Joint Surgery—American Volume, vol. 94, no. 4, pp. 335–342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. S. S. Godil, S. L. Parker, K. R. O'Neill, C. J. Devin, and M. J. McGirt, “Comparative effectiveness and cost-benefit analysis of local application of vancomycin powder in posterior spinal fusion for spine trauma: clinical article,” Journal of Neurosurgery: Spine, vol. 19, no. 3, pp. 331–335, 2013. View at Publisher · View at Google Scholar
  12. M. A. Olsen, J. J. Nepple, K. D. Riew et al., “Risk factors for surgical site infection following orthopaedic spinal operations,” The Journal of Bone & Joint Surgery Series A, vol. 90, no. 1, pp. 62–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. G. R. Rechtine, P. L. Bono, D. Cahill, M. J. Bolesta, and A. M. Chrin, “Postoperative wound infection after instrumentation of thoracic and lumbar fractures,” Journal of Orthopaedic Trauma, vol. 15, no. 8, pp. 566–569, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. M. A. Weinstein, J. P. McCabe, and F. P. Cammisa Jr., “Postoperative spinal wound infection: a review of 2,391 consecutive index procedures,” Journal of Spinal Disorders, vol. 13, no. 5, pp. 422–426, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Takahashi, A. Wada, Y. Iida et al., “Antimicrobial prophylaxis for spinal surgery,” Journal of Orthopaedic Science, vol. 14, no. 1, pp. 40–44, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Chikawa, T. Sakai, N. N. Bhatia et al., “Retrospective study of deep surgical site infections following spinal surgery and the effectiveness of continuous irrigation,” British Journal of Neurosurgery, vol. 25, no. 5, pp. 621–624, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. Olsen, J. Mayfield, C. Lauryssen et al., “Risk factors for surgical site infection in spinal surgery,” Journal of Neurosurgery, vol. 98, no. 2, supplement, pp. 149–155, 2003. View at Google Scholar · View at Scopus
  18. P. G. Campbell, S. Yadla, J. Malone et al., “Early complications related to approach in cervical spine surgery: single-center prospective study,” World Neurosurgery, vol. 74, no. 2-3, pp. 363–368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Abdul-Jabbar, S. H. Berven, S. S. Hu et al., “Surgical site infections in spine surgery: identification of microbiologic and surgical characteristics in 239 cases,” Spine, vol. 38, no. 22, pp. E1425–E1431, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. Rihn, C. Harrod, and T. J. Albert, “Revision cervical spine surgery,” Orthopedic Clinics of North America, vol. 43, no. 1, pp. 123–136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Ariyan, R. A. Marfuggi, G. Harder, and M. M. Goodie, “An experimental model to determine the effects of adjuvant therapy on the incidence of postoperative wound infection: I. Evaluating preoperative radiation therapy,” Plastic and Reconstructive Surgery, vol. 65, no. 3, pp. 328–337, 1980. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. Nuara, C. L. Sauder, and D. S. Alam, “Prospective analysis of outcomes and complications of 300 consecutive microvascular reconstructions,” Archives of Facial Plastic Surgery, vol. 11, no. 4, pp. 235–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Guetgemann, V. M. Brandenburg, M. Ketteler, J. Riehl, and J. Floege, “Unclear fever 7 weeks after renal transplantation in a 56-year-old patient,” Nephrology Dialysis Transplantation, vol. 21, no. 8, pp. 2325–2327, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. A. Kanafani, G. K. Dakdouki, O. El-Dbouni, T. Bawwab, and S. S. Kanj, “Surgical site infections following spinal surgery at a tertiary care center in Lebanon: incidence, microbiology, and risk factors,” Scandinavian Journal of Infectious Diseases, vol. 38, no. 8, pp. 589–592, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. A. M. Caputo, R. P. Dobbertien, J. M. Ferranti, C. R. Brown, K. W. Michael, and W. J. Richardson, “Risk factors for infection after orthopaedic spine surgery at a high-volume institution,” Journal of Surgical Orthopaedic Advances, vol. 22, no. 4, pp. 295–298, 2013. View at Publisher · View at Google Scholar
  26. K. L. Chaichana, M. Bydon, D. R. Santiago-Dieppa et al., “Risk of infection following posterior instrumented lumbar fusion for degenerative spine disease in 817 consecutive cases: clinical article,” Journal of Neurosurgery: Spine, vol. 20, no. 1, pp. 45–52, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. R. P. Moenster, T. W. Linneman, P. M. Finnegan, S. Hand, Z. Thomas, and J. R. McDonald, “Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime,” Clinical Microbiology and Infection, vol. 20, no. 6, pp. O384–O389, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. F. G. Barker II, “Efficacy of prophylactic antibiotic therapy in spinal surgery: a meta-analysis,” Neurosurgery, vol. 51, no. 2, pp. 391–401, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Rybak, B. Lomaestro, J. C. Rotschafer et al., “Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists,” The American Journal of Health-System Pharmacy, vol. 66, no. 1, pp. 82–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. J. Vandecasteele and A. S. de Vriese, “Recent changes in vancomycin use in renal failure,” Kidney International, vol. 77, no. 9, pp. 760–764, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. T. G. Cantú, N. A. Yamanaka-Yuen, and P. S. Lietman, “Serum vancomycin concentrations: reappraisal of their clinical value,” Clinical Infectious Diseases, vol. 18, no. 4, pp. 533–543, 1994. View at Google Scholar · View at Scopus
  32. E. D. Hermsen, M. Hanson, J. Sankaranarayanan, J. A. Stoner, M. C. Florescu, and M. E. Rupp, “Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections,” Expert Opinion on Drug Safety, vol. 9, no. 1, pp. 9–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. N. Jeffres, W. Isakow, J. A. Doherty, S. T. Micek, and M. H. Kollef, “A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia,” Clinical Therapeutics, vol. 29, no. 6, pp. 1107–1115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. T. P. Lodise, N. Patel, B. M. Lomaestro, K. A. Rodvold, and G. L. Drusano, “Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients,” Clinical Infectious Diseases, vol. 49, no. 4, pp. 507–514, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. L. K. Hidayat, D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer, “High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity,” Archives of Internal Medicine, vol. 166, no. 19, pp. 2138–2144, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. P. R. Ingram, D. C. Lye, P. A. Tambyah, W. P. Goh, V. H. Tam, and D. A. Fisher, “Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy,” The Journal of Antimicrobial Chemotherapy, vol. 62, no. 1, pp. 168–171, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. T. P. Lodise, B. Lomaestro, J. Graves, and G. L. Drusano, “Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1330–1336, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. V. Launay-Vacher, H. Izzedine, L. Mercadal, and G. Deray, “Clinical review: use of vancomycin in haemodialysis patients,” Critical Care, vol. 6, no. 4, pp. 313–316, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Kralovicovä, S. Spanik, J. Halko et al., “Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?” Journal of Chemotherapy, vol. 9, no. 6, pp. 420–426, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Dieterich, A. Puey, S. Lyn et al., “Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates,” Toxicological Sciences, vol. 107, no. 1, pp. 258–269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Pritchard, C. Baker, J. Leggett, P. Sehdev, A. Brown, and K. B. Bayley, “Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity,” The American Journal of Medicine, vol. 123, no. 12, pp. 1143–1149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. S. J. van Hal, D. L. Paterson, and T. P. Lodise, “Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 2, pp. 734–744, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Wong-Beringer, J. Joo, E. Tse, and P. Beringer, “Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy,” International Journal of Antimicrobial Agents, vol. 37, no. 2, pp. 95–101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. O. R. Colomo, F. A. Lerma, M. I. G. Pérez, J.-M. Sirvent, and M. G. Simón, “Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function,” European Journal of Clinical Microbiology & Infectious Diseases, vol. 30, no. 5, pp. 635–643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. M. J. Rybak, B. M. Lomaestro, J. C. Rotschafer et al., “Therapeutic monitoring of vancomycin in adults: summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists,” Pharmacotherapy, vol. 29, no. 11, pp. 1275–1279, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Chen, M. V. Anderson, W. K. Cheng, and M. D. Wongworawat, “Diabetes associated with increased surgical site infections in spinal arthrodesis,” Clinical Orthopaedics and Related Research, vol. 467, no. 7, pp. 1670–1673, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. W. O. Shaffer, J. L. Baisden, R. Fernand, and P. G. Matz, “An evidence-based clinical guideline for antibiotic prophylaxis in spine surgery,” The Spine Journal, vol. 13, no. 10, pp. 1387–1392, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. V. Rohde, B. Meyer, C. Schaller, and W. E. Hassler, “Spondylodiscitis after lumbar discectomy: incidence and a proposal for prophylaxis,” Spine, vol. 23, no. 5, pp. 615–620, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. W. W. Kanj, J. M. Flynn, D. A. Spiegel, J. P. Dormans, and K. D. Baldwin, “Vancomycin prophylaxis of surgical site infection in clean orthopedic surgery,” Orthopedics, vol. 36, no. 2, pp. 138–146, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. G. R. Matzke, R. W. McGory, C. E. Halstenson, and W. F. Keane, “Pharmacokinetics of vancomycin in patients with various degrees of renal function,” Antimicrobial Agents and Chemotherapy, vol. 25, no. 4, pp. 433–437, 1984. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Pea, M. Furlanut, C. Negri et al., “Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 5, pp. 1863–1867, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. R. H. Barth and N. DeVincenzo, “Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy,” Kidney International, vol. 50, no. 3, pp. 929–936, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. L. S. Welage, N. A. Mason, E. J. Hoffman et al., “Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics,” Journal of the American Society of Nephrology, vol. 6, no. 4, pp. 1284–1290, 1995. View at Google Scholar · View at Scopus
  54. D. M. Chilukuri and J. C. Shah, “Local delivery of vancomycin for the prophylaxis of prosthetic device-related infections,” Pharmaceutical Research, vol. 22, no. 4, pp. 563–572, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. B. E. Murray, “Vancomycin-resistant enterococcal infections,” The New England Journal of Medicine, vol. 342, no. 10, pp. 710–721, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Wu and D. W. Grainger, “Drug/device combinations for local drug therapies and infection prophylaxis,” Biomaterials, vol. 27, no. 11, pp. 2450–2467, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. M. A. Buttaro, M. I. Gimenez, G. Greco, L. Barcan, and F. Piccaluga, “High active local levels of vancomycin without nephrotoxicity released from impacted bone allografts in 20 revision hip arthroplasties,” Acta Orthopaedica, vol. 76, no. 3, pp. 336–340, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Klekamp, D. M. Spengler, M. J. McNamara, and D. W. Haas, “Risk factors associated with methicillin-resistant staphylococcal wound infection after spinal surgery,” Journal of Spinal Disorders, vol. 12, no. 3, pp. 187–191, 1999. View at Google Scholar · View at Scopus
  59. R. Mariappan, P. Manninen, E. M. Massicotte, and A. Bhatia, “Circulatory collapse after topical application of vancomycin powder during spine surgery,” Journal of Neurosurgery: Spine, vol. 19, no. 3, pp. 381–383, 2013. View at Publisher · View at Google Scholar · View at Scopus